首页> 美国卫生研究院文献>The Journal of Pharmacology and Experimental Therapeutics >Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
【2h】

Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain

机译:PF-04457845的机理和药理学表征:一种高强度且选择性的脂肪酸酰胺水解酶抑制剂可减轻炎性和非炎性疼痛

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The endogenous cannabinoid (endocannabinoid) anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH). Pharmacological blockade of FAAH has emerged as a potentially attractive strategy for augmenting endocannabinoid signaling and retaining the beneficial effects of cannabinoid receptor activation, while avoiding the undesirable side effects, such as weight gain and impairments in cognition and motor control, observed with direct cannabinoid receptor 1 agonists. Here, we report the detailed mechanistic and pharmacological characterization of N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide (PF-04457845), a highly efficacious and selective FAAH inhibitor. Mechanistic studies confirm that PF-04457845 is a time-dependent, covalent FAAH inhibitor that carbamylates FAAH's catalytic serine nucleophile. PF-04457845 inhibits human FAAH with high potency (kinact/Ki = 40,300 M−1s−1; IC50 = 7.2 nM) and is exquisitely selective in vivo as determined by activity-based protein profiling. Oral administration of PF-04457845 produced potent antinociceptive effects in both inflammatory [complete Freund's adjuvant (CFA)] and noninflammatory (monosodium iodoacetate) pain models in rats, with a minimum effective dose of 0.1 mg/kg (CFA model). PF-04457845 displayed a long duration of action as a single oral administration at 1 mg/kg showed in vivo efficacy for 24 h with a concomitant near-complete inhibition of FAAH activity and maximal sustained elevation of anandamide in brain. Significantly, PF-04457845-treated mice at 10 mg/kg elicited no effect in motility, catalepsy, and body temperature. Based on its exceptional selectivity and in vivo efficacy, combined with long duration of action and optimal pharmacokinetic properties, PF-04457845 is a clinical candidate for the treatment of pain and other nervous system disorders.
机译:内源性大麻素(内源性大麻素)anandamide主要被整合膜酶脂肪酸酰胺水解酶(FAAH)降解。 FAAH的药理学阻断已成为增加内源性大麻素信号传递并保留大麻素受体激活的有益作用的潜在诱人策略,同时避免了直接大麻素受体1所观察到的不良副作用,例如体重增加以及认知和运动控制障碍。激动剂。在这里,我们报告的N-哒嗪-3-基-4-(3-{[5-(三氟甲基)吡啶-2-基]氧基}亚苄基)哌啶-1-甲酰胺(PF-04457845)的详细机理和药理学表征),一种高效且选择性的FAAH抑制剂。机理研究证实,PF-04457845是时间依赖性的共价FAAH抑制剂,可使氨基甲酸酯化FAAH的催化丝氨酸亲核试剂。 PF-04457845高效抑制人FAAH(kinact / Ki = 40,300 M -1 s -1 ; IC50 = 7.2 nM),并且在体内具有极好的选择性基于活性的蛋白质谱分析。 PF-04457845的口服给药在大鼠的炎性[完全弗氏佐剂(CFA)]模型和非炎性(碘乙酸一钠)疼痛模型中均产生有效的抗伤害作用,最低有效剂量为0.1 mg / kg(CFA模型)。 PF-04457845表现出长效作用,因为单次口服1 mg / kg表现出24小时的体内功效,并伴随着FAAH活性的近乎完全抑制和脑中anandamide的最大持续升高。值得注意的是,以PF-04457845处理的小鼠(10 mg / kg)对运动性,僵直性和体温没有影响。 PF-04457845凭借其卓越的选择性和体内功效,结合长效作用和最佳药代动力学特性,是治疗疼痛和其他神经系统疾病的临床候选药物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号